Cellectis SA (NASDAQ:CLLS) hit a new 52-week low during trading on Wednesday . The company traded as low as $12.25 and last traded at $12.34, with a volume of 6420 shares trading hands. The stock had previously closed at $13.21.

CLLS has been the topic of a number of recent research reports. Citigroup reiterated a “neutral” rating and set a $22.00 price target on shares of Cellectis in a research report on Friday, May 24th. Goldman Sachs Group set a $20.00 price target on shares of Cellectis and gave the company a “hold” rating in a research report on Monday. Zacks Investment Research cut shares of Cellectis from a “hold” rating to a “sell” rating in a research report on Monday. BidaskClub cut shares of Cellectis from a “hold” rating to a “sell” rating in a research report on Friday, July 19th. Finally, BTIG Research initiated coverage on shares of Cellectis in a research report on Friday, August 9th. They set a “buy” rating and a $37.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $31.67.

The company has a quick ratio of 8.46, a current ratio of 8.47 and a debt-to-equity ratio of 0.11. The stock’s 50-day moving average is $15.04. The firm has a market cap of $562.02 million, a price-to-earnings ratio of -6.33 and a beta of 1.72.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.18). The company had revenue of $2.93 million for the quarter, compared to analysts’ expectations of $3.45 million. Cellectis had a negative net margin of 813.06% and a negative return on equity of 21.51%. As a group, sell-side analysts anticipate that Cellectis SA will post -2.6 EPS for the current year.

Several large investors have recently added to or reduced their stakes in CLLS. D. E. Shaw & Co. Inc. purchased a new stake in Cellectis in the second quarter valued at about $502,000. Cubist Systematic Strategies LLC acquired a new position in shares of Cellectis in the second quarter valued at about $103,000. Point72 Asset Management L.P. increased its holdings in shares of Cellectis by 66.9% in the second quarter. Point72 Asset Management L.P. now owns 142,500 shares of the biotechnology company’s stock valued at $2,223,000 after purchasing an additional 57,100 shares during the period. Marshall Wace LLP acquired a new position in shares of Cellectis in the second quarter valued at about $772,000. Finally, Morgan Stanley increased its holdings in shares of Cellectis by 56.6% in the second quarter. Morgan Stanley now owns 494,775 shares of the biotechnology company’s stock valued at $7,719,000 after purchasing an additional 178,865 shares during the period. 32.91% of the stock is owned by hedge funds and other institutional investors.

About Cellectis (NASDAQ:CLLS)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Featured Story: Day Trading – Risk Worth the Reward?

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.